Merit Medical Systems (MMSI) Projected to Post Earnings on Thursday

Merit Medical Systems (NASDAQ:MMSI) is projected to release its Q1 2025 earnings data after the market closes on Thursday, April 24th. Analysts expect the company to announce earnings of $0.75 per share and revenue of $352.57 million for the quarter.

Merit Medical Systems Trading Down 1.4 %

Shares of MMSI opened at $89.60 on Tuesday. The stock has a market capitalization of $5.29 billion, a PE ratio of 43.92, a P/E/G ratio of 2.34 and a beta of 0.85. The company’s fifty day moving average is $99.79 and its 200 day moving average is $100.63. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. Merit Medical Systems has a fifty-two week low of $71.57 and a fifty-two week high of $111.45.

Insider Activity at Merit Medical Systems

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 12,451 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the sale, the chief financial officer now owns 24,201 shares of the company’s stock, valued at approximately $2,391,300.81. The trade was a 33.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian G. Lloyd sold 25,000 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $99.50, for a total transaction of $2,487,500.00. Following the completion of the transaction, the insider now directly owns 38,993 shares of the company’s stock, valued at approximately $3,879,803.50. This represents a 39.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,132 shares of company stock valued at $11,139,521 in the last ninety days. Corporate insiders own 3.70% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on MMSI. Barrington Research reaffirmed an “outperform” rating and issued a $111.00 price target on shares of Merit Medical Systems in a report on Friday, April 11th. Raymond James raised their price target on Merit Medical Systems from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 31st. Piper Sandler reissued an “overweight” rating and issued a $116.00 price objective (up from $114.00) on shares of Merit Medical Systems in a research report on Wednesday, January 29th. Wells Fargo & Company cut their target price on Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group decreased their target price on Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and an average price target of $114.33.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.